Prem Watsa
Fairfax Financial Holdings
Prem Watsa IDENIX PHARMACEUTICALS LLC stake
total: 291
Fairfax Financial Holdings IDIX trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2014 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2014 Q3
According to 2026 Q2 report, Prem Watsa doesn't hold any IDENIX PHARMACEUTICALS LLC (IDIX) shares. To date, the estimated cost basis is nearly $24.09 for "buy" trades and estimated average "sell" price is $24.09. Fairfax Financial Holdings first purchased IDIX in 2014 Q2, initially acquiring 50,400 shares. Since the initial investment in IDENIX PHARMACEUTICALS LLC (IDIX), Fairfax Financial Holdings has made 1 more transaction.
When did Prem Watsa sell IDENIX PHARMACEUTICALS LLC (IDIX)?
Prem Watsa sold off the entire IDENIX PHARMACEUTICALS LLC (IDIX) position in 2014 Q3.
When did Prem Watsa buy IDENIX PHARMACEUTICALS LLC (IDIX)?
Prem Watsa first invested in IDENIX PHARMACEUTICALS LLC (IDIX) in 2014 Q2 at the reported quarter-end price of $24.09 per share.
What's the cost basis of Fairfax Financial Holdings's IDIX stake?
The estimated cost basis for IDENIX PHARMACEUTICALS LLC (IDIX) stake is around $24.09 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $24.09
- Weighted AVG sell price:
- $24.09
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.